Woman-owned Palisades Therapeutics in collaboration with the Veterans Medical Research Foundation is granted FDA clearance to begin Phase II/III COVID-outpatient oral therapeutic study that targets >80% of patients
A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection
The current study investigated whether the stress hormone receptor antagonist, PT150, would block the rewarding properties of ethanol via the glucocorticoid receptor system and attenuate other ethanol-induced effects.
"The most brilliant ideas are the ones that make you consider why we haven't always done it this way."
About Us
BUSINESS MODEL
We out-license or sell our products and intellectual property to third parties for global commercialization. Our companies have a unique paradigm. We consist of leading scientists, physicians, clinicians, lawyers and professionals working together without salary to change the world.
This site was created to keep industry insiders aware of our progress in the areas of Diagnostics, Therapeutics and Devices.
Poster featured at the 2021 California Citrus Conference
Combined Antibiotic And Glucocorticoid Antagonism As A Method For Disrupting
The Citrus Greening Life Cycle
Anthony R Arment, PhD1, Eric W Triplett, PhD2, Cody Artzner2, Neil D Theise, MD3 1 Central State University, 2University of Florida, 3Palisades Therapeutics